Fig. 2: Sensitivity of PDTOs to FGFR, CDK4/6, and endocrine therapy combinations. | npj Precision Oncology

Fig. 2: Sensitivity of PDTOs to FGFR, CDK4/6, and endocrine therapy combinations.

From: Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations

Fig. 2: Sensitivity of PDTOs to FGFR, CDK4/6, and endocrine therapy combinations.

FGFR-amplified and non-amplified PDOs were exposed to increasing concentrations of fulvestrant (A), palbociclib (B), and rogaratinib (C) monotherapy; IC50 was not reached (NR) for palbociclib or fulvestrant monotherapy in any organoid. H12-7 was moderately sensitive to rogaratinib monotherapy. D PDOs were exposed to fixed concentrations of fulvestrant and palbociclib (1 μM each) and increasing concentrations of rogaratinib; IC50s are shown for rogaratinib in the presence of fulvestrant+palbociclib. E Efficacy of increasing concentrations of camizestrant over a backbone of fixed palbociclib and rogaratinib in the ESR1-mutant PDO. F Efficacy of increasing concentrations of alpelisib over a backbone of fixed fulvestrant and rogaratinib in the PIK3CA-mutant PDO. IC50 values displayed in (E) and (F) correspond to the IC50 of camizestrant and alpelisib, respectively, over fixed backbone doublets. Error bars: standard error.

Back to article page